This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Rubella

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Rubella a mild illness caused by infection with rubivirus, an RNA togavirus. Spread of the virus is by droplets from the respiratory tract.

The only known hosts are humans (2). Individuals with rubella are most infectious during the eruption of the rash but the infectious period may vary from 7 days before to 4 days after the onset of the rash (1).

The true importance of rubella is the teratogenicity of the virus during the first trimester of pregnancy, resulting in fetal loss or congenital rubella syndrome (CRS). The risk of intrauterine transmission causing fetal damage varies with the gestational stage:

  • if <11 weeks – fetal damage in up to 90% of surviving infants, multiple defects can be seen
  • 11-16 weeks – the risk declines to about 20%
  • 16-20 weeks – fetal damage is rare, but there is a minimal risk of deafness
  • >20 weeks - no increased risk (1,3)

It is for this reason that there is an extensive immunisation program in the UK. Note that from October 2003, sero-negative women of child-bearing age and health workers who require protection against rubella are to be offered the combined measles-mumps-rubella (MMR) vaccine (4).

It is a notifiable disease in UK (2).

Click here for an example image of rubella rash

 

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.